Erratum to: Behavioral effects of the R-(+)- and S-(-)-enantiomers of the dopamine D1-like partial receptor agonist SKF 83959 in monkeys [European Journal of Pharmacology 558 (2007) 98-106] (DOI:10.1016/j.ejphar.2006.11.042);Behavioral effects of the R-(+)- and S-(-)-enantiomers of the dopamine D1-like partial receptor agonist SKF 83959 in monkeys

European Journal of Pharmacology

Volumn 558, Issue 1-3, 2007, Pages 98-106

  Desai, Rajeev I ^a   Neumeyer, John L ^a,b   Paronis, Carol A ^a,b   Nguyen, Phong ^a   Bergman, Jack ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b Brain Research Laboratories Inc   (United States)

Author keywords

(Squirrel monkey); Dopamine D1 like receptor; Enantiomer of SKF 83959; Eye blinking; Partial agonist; Schedule controlled behavior; SKF 82958

Indexed keywords

3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; ECOPIPAM; MCL 201; MCL 202; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; ENANTIOMER; EYELID REFLEX; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; TASK PERFORMANCE;

EID: 33847293729     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.08.013     Document Type: Erratum

References (59)

1. Abrahams B.S., Rutherford J.D., Mallet P.E., and Beninger R.J. Place conditioning with the dopamine D1-like receptor agonist SKF 82958 but not SKF 81297 or SKF 77434. Eur. J. Pharmacol. 343 (1998) 111-118
2. 2 agonists injected peripherally or into nucleus accumbens. Psychopharmacology 103 (1998) 271-276
3. 1 receptor efficacy. Eur. J. Pharmacol. 188 (1990) 335-347
4. Andringa G., Stoof J.C., and Cools A.R. Sub-chronic administration of the dopamine D1 antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: stable therapeutic effects and wearing-off dyskinesia. Psychopharmacology 146 (1999) 328-334
5. Andringa G., Drukarch B., Leysen J.E., Cools A.R., and Stoof J.C. The alleged dopamine D1 receptor agonist SKF 83959 is a dopamine D1 receptor antagonist in primate cells and interacts with other receptors. Eur. J. Pharmacol. 364 (1999) 33-41
6. Arnt J., Hyttel J., and Sanchez C. Partial and full dopamine D1 receptor agonists in mice and rats: relation between behavioural effects and stimulation of adenylate cyclase activity in vitro. Eur. J. Pharmacol. 213 (1992) 259-267
7. 1 agonists. Problems of Drug Dependence 1991. NIDA Research Monographs vol. 119 (1992), US Government Printing Office, Washington, DC 185-189
8. Bergman J., Kamien J.B., and Spealman R.D. Antagonism of cocaine self-administration by selective dopamine D(1) and D(2) antagonists. Behav. Pharmacol. 1 (1990) 355-363
9. 2 dopamine receptor antagonists in squirrel monkeys. J. Pharmacol. Exp. Ther. 258 (1991) 910-917
10. Bergman J., Rosenzweig-Lipson S., and Spealman R.D. Differential effects of dopamine D1 and D2 receptor agonists on schedule-controlled behavior in squirrel monkeys. J. Pharmacol. Exp. Ther. 273 (1995) 40-48
11. 2-like agonists in rats that self-administer cocaine. J. Pharmacol. Exp. Ther. 291 (1999) 353-360
12. Caldwell J. Do single enantiomers have something special to offer?. Hum. Psychopharmacol. 16 (2001) S67-S71
13. Clifford J.J., Tighe O., Croke D.T., Kinsella A., Sibley D.R., Drago J., and Waddington J.L. Conservation of behavioural topography to dopamine D1-like receptor agonists in mutant mice lacking the D1A receptor implicates a D1-like receptor not coupled to adenylyl cyclase. Neuroscience 93 (1999) 1483-1489
14. Cools A.R., Lubbers L., van Oosten R.V., and Andringa G. SKF 83959 is an antagonist of dopamine D1-like receptors in the prefrontal cortex and nucleus accumbens: a key to its antiparkinsonian effect in animals?. Neuropharmacology 42 (2002) 237-245
15. Corrigall W.A., and Coen K.M. Cocaine self-administration is increased by both D1 and D2 dopamine antagonists. Pharmacol. Biochem. Behav. 39 (1991) 799-802
16. Daly S.A., and Waddington J.L. D1 dopamine receptors and the topography of unconditioned motor behavior: studies with the selective 'full efficacy' benzazepine D1 agonist SKF 83189. J. Psychopharmacol. 6 (1992) 50-60
17. Desai R.I., Terry P., and Katz J.L. Comparison of the discriminative-stimulus effects of SKF 38393 with those of other dopamine receptor agonists. Behav. Pharmacol. 14 (2003) 223-228
18. Desai R.I., Terry P., and Katz J.L. A comparison of the locomotor stimulant effects of D1-like receptor agonists in mice. Pharmacol. Biochem. Behav. 81 (2005) 843-848
19. Deveney A.M., and Waddington J.L. Pharmacological characterization of behavioural responses to Sk&F 83959 in relation to 'D1-like' dopamine receptors not linked to adenylyl cyclase. Br. J. Pharmacol. 116 (1995) 2120-2126
20. Downes R.P., and Waddington J.L. Grooming and vacuous chewing induced by SK&F 83959, and agonist of dopamine 'D1-like' receptors that inhibits dopamine-sensitive adenylyl cyclase. Eur. J. Pharmacol. 234 (1993) 135-136
21. 2 analysis. Psychopharmacology 4 (1988) 107-121
22. 2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey. J. Pharmacol. Exp. Ther. 259 (1992) 595-600
23. Finney DJ. Statistical Methods in Biological Assay. 2nd edn. (1964), Hafner, New York
24. Fornaguera J., Huston J.P., Carey R.J., and Schwarting R.K. Stimulation of D1- or D2-receptors in drug-naive rats with different degrees of unilateral nigro-striatal dopamine lesions. Psychopharmacology 119 (1995) 145-154
25. Gnanalingham K., Erol D., Hunter A., Smith L., Jenner P., and Marsden C.A. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset. Psychopharmacology 117 (1995) 275-286
26. Gnanalingham K., Hunter A.J., Jenner P., and Mardens C.D. Stimulation of adenylate cyclase activity by benzazepine D-1 dopamine agonists with varying efficacies in the 6-hydroxydopamine lesioned rat-relationship to circling behavior. Biochem. Pharm. 49 (1995) 1185-1193
27. Gnanalingham K.K., Hunter A.J., Jenner P., and Marsden C.D. The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease. Psychopharmacology 117 (1995) 287-297
28. Henry D.J., Hu X.T., and White F.J. Adaptations in the mesoaccumbens dopamine system resulting from repeated administration of dopamine D1 and D2 receptor-selective agonists: relevance to cocaine sensitization. Psychopharmacology 140 (1998) 233-242
29. Jutkiewicz E.M., and Bergman J. Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions. J. Pharmacol. Exp. Ther. 311 (2004) 1008-1015
30. 1 dopamine receptor agonist, SKF 38393, on behavior maintained by cocaine injection in squirrel monkeys. Psychopharmacology 109 (1992) 241-244
31. Katz J.L., Shores A.E., and Witkin J.M. Effects of D1 dopamine agonists on schedule-controlled behavior in the squirrel monkey. Behav. Pharm. 6 (1995) 143-148
32. Katz J.L., Kopajtic T.A., Myers K.A., Mitkus R.J., and Chider M. Behavioral effects of cocaine: interactions with D1 dopaminergic antagonists and agonists in mice and squirrel monkeys. J. Pharmacol. Exp. Ther. 291 (1999) 265-279
33. Kebabian J.W., and Calne D.B. Multiple receptors for dopamine. Nature 277 (1979) 93-96
34. Kelleher R.T., and Morse W.H. Determinants of the specificity of behavioral effects of drugs. Ergeb. Physiol. Biol. Chem. Exp. Pharmakol. 60 (1968) 1-56
35. Kleven M.S., and Koek W. Differential effects of direct and indirect dopamine agonists on eye blink rate in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 279 (1996) 1211-1219
36. 2+ mobilization in Xenopus oocytes. Proc. Natl. Acad. Sci. U. S. A 87 (1990) 2196-2200
37. Mendelson J.H., and Mello N.K. Management of cocaine abuse and dependence. New Engl. J. Med. 334 (1996) 965-972
38. Morelli M., Fenu S., Pinna A., Cozzolino A., Carta A., and Di Chiara G. 'Priming' to dopamine agonist-induced contralateral turning as a model of non-associative sensitization to the expression of the post-synaptic dopamine message. Behav. Pharmacol. 4 (1993) 389-397
39. 1 receptor partial agonist SKF 77434 on cocaine self-administration in rhesus monkeys. Psychopharmacology 160 (2002) 362-370
40. Neumeyer J.L., Kula N.S., Baldessarini R.J., and Baindur N. Stereoisomeric probes for the D1 dopamine receptor: synthesis and characterization of R(+) and S(-) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analogue. J. Med. Chem. 35 (1992) 1466-1471
41. Neumeyer J.L., Kula N.S., Bergman J., and Baldessarini R.J. Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazpines. Eur. J. Pharmacol. 474 (2003) 137-140
42. Peacock L., and Gerlach J. Aberrant behavioral effects of a dopamine D1 receptor antagonist and agonist in monkeys: evidence of uncharted dopamine D1 receptor actions. Biol. Psychiatry 50 (2001) 501-509
43. Platt D.M., Rowlett J.K., and Spealman R.D. Dissociation of cocaine-antagonist properties and motoric effects of the D1 receptor partial agonists SKF 83959 and SKF 77434. J. Pharmacol. Exp. Ther. 293 (2000) 1017-1026
44. Platt D.M., Rowlett J.K., and Spealman R.D. Modulation of cocaine and food self-administration by low- and high-efficacy D1 agonists in squirrel monkeys. Psychopharmacology 157 (2001) 208-216
45. Platt D.M., Rowlett J.K., and Spealman R.D. Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology 163 (2002) 265-282
46. 1 agonists SKF 82958 and SKF 77434 are self-administered by rats. Brain Res. 582 (1992) 349-352
47. Singh J., Desiraju T., and Raju T.R. Dopamine receptor sub-types involvement in nucleus accumbens and ventral tegmentum but not in medial prefrontal cortex: on self-stimulation of lateral hypothalamus and ventral mesencephalon. Behav. Brain Res. 86 (1997) 171-179
48. Sinnott R.S., and Nader M.A. Modulation of cocaine's discriminative stimulus effects by dopamine D(1) agonists in rhesus monkeys. Pharmacol. Biochem. Behav. 68 (2001) 301-309
49. Snedecor G.W., and Cochran WG. Statistical Methods. 6th edn. (1967), Iowa State University Press, Ames, Iowa
50. Spealman R.D., Bergman J., and Rosenzweig-Lipson S. Differential modulation of behavioral effects of cocaine by low- and high-efficacy D1 agonists. Psychopharmacology 133 (1997) 283-292
51. Spealman R.D., Barrett-Larimore R.L., Rowlett J.K., Platt D.M., and Khroyan T.V. Pharmacological and environmental determinants of relapse to cocaine-seeking behavior. Pharmacol. Biochem. Behav. 64 (1999) 327-336
52. Tidey J.W., and Bergman J. Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs. J. Pharmacol. Exp. Ther. 285 (1998) 1-12
53. Undie A.S. Relationship between dopamine agonist stimulation of inositol phosphate formation and cytidine diphosphate-diacylglycerol accumulation in brain slices. Brain Res. 816 (1999) 286-294
54. 1 receptor enhances inositol phosphates formation in rat brain. J. Pharmacol. Exp. Ther. 253 (1990) 987-992
55. Undie A.S., Weinstock J., Sarau H.M., and Friedman E. Evidence for a distinct D1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. J. Neurochem. 622 (1994) 2045-2048
56. Undie A.S., Berki A.C., and Beardsley K. Dopaminergic behaviors and signal transduction mediated through adenylate cyclase and phospholipase C pathways. Neuropharmacology 39 (2000) 75-87
57. Waddington J.L., Daly S.A., Downes R.P., Deveney A.M., McCauley P.G., and O'Boyle K.M. Behavioural pharmacology of 'D-1-like' dopamine receptors: further subtyping, new pharmacological probes and interactions with 'D-2-like' receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 19 (1995) 811-831
58. Weed M.R., and Woolverton W.L. The reinforcing effects of dopamine D1 receptor agonists in rhesus monkeys. J. Pharmacol. Exp. Ther. 275 (1995) 1367-1374
59. Weed M.R., Paul I.A., Dwoskin L.P., Moore S.E., and Woolverton W.L. The relationship between reinforcing effects and in vitro effects of D1 agonists in monkeys. J. Pharmacol. Exp. Ther. 283 (1997) 29-38